<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10162">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00686712</url>
  </required_header>
  <id_info>
    <org_study_id>03-02-524</org_study_id>
    <secondary_id>U54RR014616</secondary_id>
    <nct_id>NCT00686712</nct_id>
  </id_info>
  <brief_title>Insulin Glargine at Bedtime or in AM Versus NPH</brief_title>
  <official_title>The Utility of Insulin Glargine (Lantus) Compared to NPH in Ethnic Minority Type 2 Diabetic Subjects Starting Insulin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles Drew University of Medicine and Science</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Charles Drew University of Medicine and Science</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of once-nightly insulin glargine versus a single morning
      injection of glargine or once-nightly NPH insulin in ethnic minority type 2 diabetic
      patients inadequately controlled on combination oral agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insulin glargine has a longer action than compared to NPH insulin, but whether this results
      in improved control when used as a once-nightly or morning basal insulin injection in type 2
      diabetic patients who are inadequately controlled on combination oral agents has been
      controversial. Inner city ethnic minority patients with diabetes are a particularly
      challenging population of diabetic patients to treat. This study investigates whether
      insulin glargine may be a more effective or safer first-line basal insulin than NPH in this
      population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hemoglobin A1c Change From Baseline</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Glucose Readings &lt; 130 mg/dL</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Total Hypoglycemic Reactions</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Severe Hypoglycemic Reactions</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index Change From Baseline</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Insulin Dose</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Adverse Event Other Than Hypoglycemia</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin glargine at bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin glargine at AM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NPH insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>Insulin glargine at bedtime (dose titrated to maintain 50% of fasting glucose readings &lt;120 mg/dL)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Trade name: Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>Insulin glargine in AM (dose titrated to maintain 50% of pre-supper glucose readings &lt;120 mg/dL)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Trade name: Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPH insulin</intervention_name>
    <description>NPH insulin at bedtime (dose titrated to maintain 50% of fasting glucoses &lt;120 mg/dL)</description>
    <arm_group_label>3</arm_group_label>
    <other_name>(Generic)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age 18-75

          -  Type 2 diabetes diagnosed for at least 1 year

          -  Treatment with stable doses of oral agents (alone or in combination) for at least 2
             months

          -  Inadequate glycemic control (hemoglobin A1c â‰¥ 7.5%) on maximum-tolerated doses of a
             sulfonylurea, metformin and a thiazolidinedione

          -  No past history of chronic insulin use (other than treatment of gestational diabetes
             or hospitalizations of less than 1 week in duration)

          -  Hemoglobin A1c between 7.5% and 12%

          -  Body mass index (BMI) between 20 and 40 kg/m2

        Exclusion Criteria:

          -  Current or previous chronic use of insulin (other than for treatment of gestational
             diabetes)

          -  History of confirmed (or clinical suspicion of) type 1 diabetes

          -  Female subjects of childbearing potential who are sexually active and not using a
             reliable form of contraception

          -  Current pregnancy or lactation.

          -  Subjects for whom insulin therapy is contraindicated or for whom, in the opinion of
             the investigator, therapy with insulin is not indicated

          -  Subjects with advanced proliferative diabetic retinopathy

          -  Subjects who work night shifts or who are unable to stay on a consistent daily meal
             schedule

          -  History of any clinically significant renal, hepatic, cardiovascular, neurological,
             endocrinological or other major systemic disease that, in the opinion of the
             investigator, may make implementation of the protocol or interpretation of the data
             difficult.

          -  Subjects who will likely require or initiate therapy with drugs which may interfere
             with glucose metabolism during the course of the study

          -  Subjects who are in another investigational study or have received another
             investigational medication within 30 days of study entry

          -  Subjects who are unable or unwilling to comply with all components of the study
             protocol, including contacting the investigators at specified times and attending all
             scheduled follow-up visits.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley Hsia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles Drew University of Medicine and Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charles Drew University of Medicine and Science</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 2, 2016</lastchanged_date>
  <firstreceived_date>May 27, 2008</firstreceived_date>
  <firstreceived_results_date>September 15, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glargine</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Basal insulin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glargine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred from Sep 2002 to Feb 2009. Subjects recruited from a diabetes specialty referral clinic, as well as from primary care clinics and through advertising in the South Los Angeles area.</recruitment_details>
      <pre_assignment_details>Baseline run-in period to document baseline control and reinforce dietary/lifestyle principles.
23 subjects not randomized due to protocol violations, loss to follow-up, lack of need for insulin, or voluntarily.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Insulin Glargine at Bedtime</title>
          <description>Bedtime insulin glargine titrated to morning fasting glucose readings</description>
        </group>
        <group group_id="P2">
          <title>Insulin Glargine in AM</title>
          <description>Morning insulin glargine titrated to pre-supper glucose readings</description>
        </group>
        <group group_id="P3">
          <title>NPH Insulin</title>
          <description>Bedtime NPH insulin titrated to morning fasting glucose readings</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Insulin Glargine at Bedtime</title>
          <description>Bedtime insulin glargine titrated to morning fasting glucose readings</description>
        </group>
        <group group_id="B2">
          <title>Insulin Glargine in AM</title>
          <description>Morning insulin glargine titrated to pre-supper glucose readings</description>
        </group>
        <group group_id="B3">
          <title>NPH Insulin</title>
          <description>Bedtime NPH insulin titrated to morning fasting glucose readings</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="30"/>
                <measurement group_id="B4" value="85"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="50.3" spread="11.2"/>
                <measurement group_id="B2" value="53.0" spread="8.6"/>
                <measurement group_id="B3" value="53.2" spread="7.7"/>
                <measurement group_id="B4" value="52.1" spread="9.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="21"/>
                <measurement group_id="B4" value="49"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="9"/>
                <measurement group_id="B4" value="36"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="25"/>
                <measurement group_id="B4" value="70"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="5"/>
                <measurement group_id="B4" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c</title>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="9.2" spread="1.3"/>
                <measurement group_id="B2" value="9.6" spread="1.2"/>
                <measurement group_id="B3" value="9.3" spread="1.6"/>
                <measurement group_id="B4" value="9.3" spread="1.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Diabetes Duration</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="9.0" spread="5.9"/>
                <measurement group_id="B2" value="9.5" spread="5.2"/>
                <measurement group_id="B3" value="7.8" spread="4.2"/>
                <measurement group_id="B4" value="8.7" spread="5.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="31.6" spread="5.0"/>
                <measurement group_id="B2" value="31.1" spread="5.2"/>
                <measurement group_id="B3" value="32.1" spread="6.0"/>
                <measurement group_id="B4" value="31.6" spread="5.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hemoglobin A1c Change From Baseline</title>
        <time_frame>Baseline to 6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine at Bedtime</title>
            <description>Bedtime insulin glargine titrated to morning fasting glucose readings</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine in AM</title>
            <description>Morning insulin glargine titrated to pre-supper glucose readings</description>
          </group>
          <group group_id="O3">
            <title>NPH Insulin</title>
            <description>Bedtime NPH insulin titrated to morning fasting glucose readings</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="25"/>
                  <measurement group_id="O3" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Hemoglobin A1c Change From Baseline</title>
            <units>Percent</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.3" spread="1.2"/>
                  <measurement group_id="O2" value="-1.9" spread="1.4"/>
                  <measurement group_id="O3" value="-1.4" spread="1.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Glucose Readings &lt; 130 mg/dL</title>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Total Hypoglycemic Reactions</title>
        <time_frame>6 months</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Severe Hypoglycemic Reactions</title>
        <time_frame>6 months</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index Change From Baseline</title>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Insulin Dose</title>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Any Adverse Event Other Than Hypoglycemia</title>
        <time_frame>6 months</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Insulin Glargine at Bedtime</title>
          <description>Bedtime insulin glargine titrated to morning fasting glucose readings</description>
        </group>
        <group group_id="E2">
          <title>Insulin Glargine in AM</title>
          <description>Morning insulin glargine titrated to pre-supper glucose readings</description>
        </group>
        <group group_id="E3">
          <title>NPH Insulin</title>
          <description>Bedtime NPH insulin titrated to morning fasting glucose readings</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Foot Infection (Hospitalization)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Symptomatic Hypoglycemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Classic symptoms of hypoglycemia, relieved by carbohydrate ingestion, with or without a corroborating self-monitored glucose reading</description>
                <counts group_id="E1" events="200" subjects_affected="23" subjects_at_risk="30"/>
                <counts group_id="E2" events="239" subjects_affected="24" subjects_at_risk="25"/>
                <counts group_id="E3" events="247" subjects_affected="23" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Asymptomatic Retinal Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to smaller than anticipated enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Stanley H. Hsia, MD</name_or_title>
      <organization>Charles R. Drew University of Medicine and Science</organization>
      <phone>323-357-3633</phone>
      <email>stanleyhsia@cdrewu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
